Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 05 Jul 2023
in accordance with U. S. A study that was published online on June 28 in JAMA Network Open found a positive correlation between penalty increases and the Centers for Medicare and Medicaid Services (CMS) Price Transparency Rule.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge